Haleos Labs Ltd (HALEOSLABS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Haleos Labs Ltd on NSE and BSE, with an AI summary of each filing.
Dividend payable to shareholders who have not yet updated their KYC details is withheld and shall be released upon compliance with the KYC norms.
Dividend · 31 Oct 2026, 8:51 pm
Haleos Labs Withholds FY26 Dividend Pending Shareholder KYC Updation Haleos Labs Limited has temporarily withheld dividend payments for FY26—approved at 15% (₹1.50 per equity share of face value ₹10) at its 20th AGM on 30th Sep'26—for shareholders who have not updated KYC or bank details per SEBI norms. On 31st Oct'26, the company issued intimation letters to affected physical and demat shareholders requesting mandatory submission of PAN, bank mandates, and relevant ISR/SH forms via its RTA, Aarthi Consultants. Withheld dividends will be released directly to registered bank accounts upon KYC verification.
Enclosed
Annual General Meeting · 02 Oct 2026, 2:06 am
Haleos Labs 20th AGM Voting Results and Resolutions Approval Haleos Labs Limited announced that all eight resolutions at its 20th AGM held on 30th Sep'26 were approved with requisite majority via remote and meeting e-voting. Key approvals include the adoption of FY26 audited financial statements, declaration of FY26 dividend, statutory auditor appointments, and ratification of cost auditor remuneration. Shareholders also approved the re-appointment and remuneration revision of Managing Director Mr. TVVSN Murthy, alongside the re-appointment of Independent Directors Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam, with >99.99% votes polled in favor across items.
Enclosed
Annual General Meeting · 01 Oct 2026, 12:44 am
Haleos Labs Concludes 20th AGM, Approves 15% Dividend and Key Director Appointments Haleos Labs Limited conducted its 20th AGM on 30th Sep'26 via video conference. Key resolutions tabled for shareholder approval included the adoption of annual accounts for the year ended 31st Mar'26, declaration of a 15% dividend, and the reappointment of Managing Director TVSN Murthy alongside a revision in his remuneration. Additionally, shareholders voted on the re-appointment of Independent Directors Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam, as well as the appointment of statutory auditors for a five-year term. Voting results will be disclosed separately.
Update on the material subsidiary of the Company.
Others (Uncategorized) · 18 Sept 2026, 5:22 pm
Haleos Labs Subsidiary Clears US-FDA Inspection with Zero Observations US-FDA successfully concluded an inspection at Mahi Drugs Private Limited, a material subsidiary of Haleos Labs Limited, with zero Form 483 observations. The audit took place from 15th Sep'26 to 18th Sep'26 at its API manufacturing facility in Parawada, Anakapalli, Andhra Pradesh. This matches the clean outcome achieved during the facility's previous US-FDA inspection in Jan'25, reaffirming adherence to regulatory compliance and quality standards.
Communication to physical shareholders providing them with the link to the Annual Report and AGM Notice.
Annual General Meeting · 10 Sept 2026, 12:28 am
Enclosed newspaper advertisement for the AGM Notice.
Annual General Meeting · 08 Sept 2026, 10:56 pm
Enclosed - 20th AGM Notice.
Annual General Meeting · 08 Sept 2026, 10:38 pm
Enclosed Annual Report for the year ended 31st March, 2026.
Others (Uncategorized) · 08 Sept 2026, 10:04 pm
The record date for the dividend (F26) and the 20th AGM will be Wednesday, September 23, 2026.
Dividend · 06 Sept 2026, 12:30 am
Events calendar for the 20th Annual General Meeting.
Annual General Meeting · 06 Sept 2026, 12:22 am
Enclosed email communication sent to Shareholders.
Others (Uncategorized) · 24 Aug 2026, 8:34 pm
Haleos Labs Declares FY26 Final Dividend; Sets Record Date Haleos Labs' board has recommended a final dividend of ₹1.50 per share (15% of face value) for the financial year ended 31 Mar'26, subject to shareholder approval. The record date for determining shareholder eligibility is set for 23 Sep'26. The dividend is taxable, and the company will deduct TDS at applicable rates. Shareholders must submit required tax documents by 25 Sep'26 to ensure appropriate tax withholding. The announcement details various TDS rates for resident and non-resident shareholders, including a 10% rate for most residents with a valid PAN.
Enclosed -- newspaper advertisement for Q1F27 results.
Others (Uncategorized) · 07 Aug 2026, 6:37 pm
Haleos Labs Reports Weaker Q1 FY27 Results YoY Haleos Labs reported weaker consolidated results for Q1 FY27 (quarter ended 30 Jun'26). Total income fell 11.6% YoY to ₹7,294.23 lakhs. Net Profit After Tax (PAT) declined 58.0% YoY to ₹184.03 lakhs from ₹438.21 lakhs. Consequently, basic EPS dropped to ₹8.75 from ₹13.75 in the prior year's quarter. On a standalone basis, PAT decreased by 37.2% YoY to ₹323.78 lakhs, while total income from operations was down 14.2% YoY to ₹6,782.97 lakhs. The board approved the results on 05 Aug'26.
Mahi Drugs Private Limited appointed Cost Auditors for the year 2026-27 and Mr. Vincent P Asrao as Nominee Director.
Change in Auditor · 05 Aug 2026, 8:45 pm
Haleos Labs Announces Appointments at Material Subsidiary Mahi Drugs Haleos Labs reported key appointments at its material subsidiary, Mahi Drugs Private Limited, effective 5th Aug'26. Annapragada & Co. has been appointed as Cost Auditors for the 2026-27 financial year. Additionally, Mr. Vincent P. Asaro has been appointed as Nominee Director, nominated by ChemWerth Inc., replacing Mr. M. Madhu Rao. Mr. Asaro is the President of ChemWerth and brings over 35 years of pharmaceutical industry experience, having previously served as its CFO and held positions at Deloitte and Bayer.
Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam were reappointed for a second term of 5 years w.e.f. November 13, 2026, subject to approval of shareholders.
Others (Uncategorized) · 05 Aug 2026, 8:03 pm
Haleos Labs Board Approves Reappointment of Two Independent Directors On 05 Aug'26, the Board of Haleos Labs Limited approved the reappointment of two Independent Directors, Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam, for a second consecutive five-year term. The new term is effective from 13 Nov'26, subject to shareholder approval. Their current tenures are set to expire on 12 Nov'26. Both directors have no inter-se relationships and are not debarred by any SEBI orders. This provides leadership continuity on the company's board.
Enclosed - Outcome of 98th Board meeting.
Outcome · 05 Aug 2026, 7:19 pm
Haleos Labs Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 7,294 (-11.6% YoY | -2.9% QoQ) ■ EBITDA: 912 (-22.1% YoY | +119.2% QoQ) ■ EBITDA Margin (%): 12.5 (-169 bps YoY | +697 bps QoQ) ■ PAT: 265 (-36.3% YoY | +507.6% QoQ) ■ EPS (INR): 8.75 (-36.4% YoY | +507.6% QoQ)
Haleos Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve the unaudited financial results ....
Intimation · 05 Aug 2026, 5:30 am
Enclosed - Newspaper advertisement.
Others (Uncategorized) · 30 Jul 2026, 6:14 pm
Haleos Labs Publishes Newspaper Advertisement for Postal Ballot Haleos Labs Limited announced it has published newspaper advertisements on Jul 30, '26, regarding its Postal Ballot conducted via remote e-voting. The voting period was from May 29, '26, to Jul 29, '26. The company also publicized the opening of a "Special Window" in compliance with a SEBI circular dated Jan 30, '26. The advertisements appeared in the Business Standard (English) and Telugu Prabha (Telugu) newspapers. The company was formerly known as SMS Lifesciences India Limited.
Communication to shareholders regarding transfer of shares to the IEPF suspense account for the unclaimed dividend for the year 2018-19.
Dividend · 16 Jun 2026, 11:57 pm
Haleos Labs Notifies Shareholders of Share Transfer to IEPF Haleos Labs has notified shareholders regarding the compulsory transfer of shares to the Investor Education & Protection Fund (IEPF) Suspense Account. This action pertains to shares for which the dividend for FY 2018-19 has remained unpaid or unclaimed for seven consecutive years. A public notice was issued on 16 Jun'26, and individual communications have been dispatched. Shareholders must claim their unpaid dividends by 5 Nov'26 to prevent their corresponding shares from being transferred to the IEPF account.
In lieu of change in Board composition, the Board Committees are reconstituted.
Others (Uncategorized) · 02 Jun 2026, 9:06 pm
Haleos Labs Reconstitutes Board Committees Following Board Composition Change Haleos Labs reconstituted its board sub-committees on May 29, '26, following a change in board composition. The Audit Committee will be chaired by Independent Director (ID) P. Sarath Kumar. The Nomination & Remuneration Committee will be chaired by ID Mannam Malakondaiah. The Corporate Social Responsibility Committee will be led by Executive Director (ED) TVVSN Murthy. Finally, the Stakeholders Relationship Committee will be chaired by ID P. Sarath Kumar. These changes impact key governance and oversight functions within the company.
Enclosed - newspaper advertisement for Q4 results.
Others (Uncategorized) · 02 Jun 2026, 8:30 pm
Haleos Labs Reports Q4 & FY26 Results with Strong YoY Profit Growth Haleos Labs reported financial results for the quarter and year ended 31 Mar '26. Q4FY26 Net Profit stood at ₹96.27 crores compared to ₹109.11 crores in Q4FY25. Total Income for the quarter was ₹344.60 crores versus ₹369.27 crores YoY. For the full year FY26, Net Profit surged to ₹360.55 crores from ₹302.83 crores in FY25, while FY26 Total Income reached ₹1,805.24 crores, up from ₹1,783.33 crores YoY. The board recommended a dividend of ₹1 (100%) per equity share.
Enclosed financial results for the quarter and year ended 31st March, 2026.
Financial Result · 30 May 2026, 7:53 pm
Haleos Labs Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 7,514 (-15.7% YoY | -20.7% QoQ) ■ EBITDA: 416 (-43.9% YoY | -70.4% QoQ) ■ EBITDA Margin (%): 5.5 (-279 bps YoY | -929 bps QoQ) ■ PAT: 43.6 (-85.3% YoY | -93.4% QoQ) ■ EPS (INR): 1.44 (-85.4% YoY | -93.4% QoQ)
Reappointment of Mrs Sudeepthi Gopineedi as whole-time Director for a further period of 5 years w.e.f. Sept 2, 2026, subject to approval of Shareholders.
Change in Management · 30 May 2026, 1:40 am
Haleos Labs Board Reappoints Sudeepthi Gopineedi as Whole-Time Director Haleos Labs' Board of Directors approved the reappointment of Mrs. Sudeepthi Gopineedi as Whole-Time Director on 29 May'26. The reappointment is for a five-year term effective 02 Sep'26, subject to shareholder approval. The decision ensures leadership continuity as her current term ends on 01 Sep'26. Mrs. Gopineedi is the daughter of the Managing Director, Mr. TVVSN Murthy, and the sister of Executive Director, Mr. Talluri Venkata Praveen. She is not debarred from holding the directorship position.
Enclosed are the details related to the appointment of Statutory Auditors and Cost Auditors.
Change in Auditor · 30 May 2026, 1:37 am
Haleos Labs Appoints New Statutory Auditors for a Five-Year Term On 29 May'26, Haleos Labs' board approved the appointment of Suryanarayana & Suresh as statutory auditors for a five-year term, starting from the 20th AGM until the 25th AGM. This follows the upcoming completion of the second term of the existing auditors, Rambabu & Co. The appointment is subject to shareholder approval. Additionally, the board reappointed Annapragada & Co. as cost auditors for the fiscal year 2026-27, which also requires shareholder approval for remuneration.
Resignation of Mrs. Sundaramma Patilbandla from the post of Independent Director w.e.f. May 29, 2026.
Change in Management · 30 May 2026, 1:32 am
Haleos Labs Announces Independent Director Resignation Sundaramma Patibandla has resigned as Independent Director of Haleos Labs, effective 29 May'26, citing personal and professional commitments. Consequently, she also ceases to be a member of the Audit, Nomination & Remuneration, and Stakeholders' Relationship committees. The company confirmed there are no other material reasons for her departure and stated its Board composition remains in compliance with SEBI regulations post-resignation. Patibandla confirmed she holds no directorships in other listed entities.
Enclosed - Outcome of 97th Board meeting.
Outcome · 29 May 2026, 9:19 pm
Haleos Labs Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 7,514 (-15.7% YoY | -20.7% QoQ) ■ EBITDA: 416 (-43.9% YoY | -70.4% QoQ) ■ EBITDA Margin (%): 5.5 (-279 bps YoY | -929 bps QoQ) ■ PAT: 43.6 (-85.3% YoY | -93.4% QoQ) ■ EPS (INR): 1.44 (-85.4% YoY | -93.4% QoQ)